26.27
price up icon0.36%   0.10
 
loading
Schlusskurs vom Vortag:
$26.17
Offen:
$26.43
24-Stunden-Volumen:
43,085
Relative Volume:
0.05
Marktkapitalisierung:
$3.84B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-272.55M
KGV:
-13.61
EPS:
-1.93
Netto-Cashflow:
$-243.55M
1W Leistung:
-6.36%
1M Leistung:
-10.57%
6M Leistung:
-13.32%
1J Leistung:
-20.31%
1-Tages-Spanne:
Value
$26.18
$26.46
1-Wochen-Bereich:
Value
$24.61
$28.04
52-Wochen-Spanne:
Value
$24.61
$45.58

Immunovant Inc Stock (IMVT) Company Profile

Name
Firmenname
Immunovant Inc
Name
Telefon
917-580-3099
Name
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Name
Mitarbeiter
207
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
IMVT's Discussions on Twitter

Vergleichen Sie IMVT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
IMVT 26.27 3.84B 0 -272.55M -243.55M -1.93
VRTX 445.46 115.74B 10.63B -479.80M -1.35B 13.33
REGN 736.00 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 585.04 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 247.45 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.20 24.49B 3.30B -501.07M 1.03B 11.54

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-10-13 Hochstufung UBS Neutral → Buy
2023-09-26 Hochstufung Raymond James Mkt Perform → Outperform
2023-05-01 Eingeleitet BofA Securities Buy
2023-04-25 Eingeleitet Citigroup Buy
2023-03-31 Eingeleitet Piper Sandler Overweight
2023-03-30 Eingeleitet Stifel Buy
2023-02-15 Eingeleitet Cantor Fitzgerald Overweight
2023-02-13 Hochstufung Guggenheim Neutral → Buy
2023-01-03 Hochstufung Wells Fargo Equal Weight → Overweight
2022-09-26 Herabstufung UBS Buy → Neutral
2021-12-08 Eingeleitet Wells Fargo Equal Weight
2021-08-03 Herabstufung Robert W. Baird Outperform → Neutral
2021-08-02 Herabstufung Credit Suisse Neutral → Underperform
2021-06-01 Herabstufung Guggenheim Buy → Neutral
2021-06-01 Herabstufung Stifel Buy → Hold
2020-10-28 Eingeleitet UBS Buy
2020-10-12 Eingeleitet Guggenheim Buy
2020-10-08 Eingeleitet Stifel Buy
2020-10-02 Eingeleitet Credit Suisse Outperform
2020-08-26 Bestätigt H.C. Wainwright Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-07-29 Eingeleitet H.C. Wainwright Buy
2020-02-24 Eingeleitet SVB Leerink Outperform
Alle ansehen

Immunovant Inc Aktie (IMVT) Neueste Nachrichten

pulisher
Nov 20, 2024

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Immunovant stock hits 52-week low at $24.66 amid market shifts - Investing.com Nigeria

Nov 20, 2024
pulisher
Nov 13, 2024

Principal Financial Group Inc. Purchases 391,436 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

(IMVT) Technical Data - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Acquisition of Immunovant Inc Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 11, 2024

Immunovant: Pipeline Progressing With One Minor Delay (NASDAQ:IMVT) - Seeking Alpha

Nov 11, 2024
pulisher
Nov 09, 2024

Immunovant (NASDAQ:IMVT) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Analysts Provide An Important Insights On Immunovant Inc (IMVT) - Stocks Register

Nov 09, 2024
pulisher
Nov 08, 2024

Immunovant’s Strategic Advances in Autoimmune Therapies - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

Interesting IMVT Put And Call Options For March 2025 - Nasdaq

Nov 08, 2024
pulisher
Nov 08, 2024

Immunovant's (IMVT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Immunovant Inc (IMVT) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses | IMVT Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Immunovant Breaks Above 200-Day Moving AverageBullish for IMVT - Nasdaq

Nov 06, 2024
pulisher
Nov 04, 2024

Emerald Mutual Fund Advisers Trust Has $5.24 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Where are the Opportunities in (IMVT) - Stock Traders Daily

Nov 02, 2024
pulisher
Nov 02, 2024

Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - Defense World

Nov 02, 2024
pulisher
Nov 02, 2024

Immunovant, Inc. (NASDAQ:IMVT) Position Boosted by abrdn plc - MarketBeat

Nov 02, 2024
pulisher
Oct 30, 2024

Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - The Manila Times

Oct 29, 2024
pulisher
Oct 29, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - ForexTV.com

Oct 29, 2024
pulisher
Oct 26, 2024

Immunovant's chief medical officer sells $94,171 in stock By Investing.com - Investing.com Canada

Oct 26, 2024
pulisher
Oct 25, 2024

Immunovant CTO Jay Stout sells $80,912 in stock By Investing.com - Investing.com Canada

Oct 25, 2024
pulisher
Oct 25, 2024

Immunovant, Inc. (NASDAQ:IMVT) CTO Sells $80,912.20 in Stock - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Immunovant CTO Jay Stout sells $80,912 in stock - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

Immunovant's chief medical officer sells $94,171 in stock - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

Immunovant's chief legal officer Mark Levine sells shares worth $128,780 By Investing.com - Investing.com Australia

Oct 25, 2024
pulisher
Oct 25, 2024

Immunovant's chief legal officer Mark Levine sells shares worth $128,780 - Investing.com

Oct 25, 2024
pulisher
Oct 19, 2024

Immunovant CFO Eva Renee Barnett sells $94,172 in stock By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 19, 2024

Immunovant's chief medical officer William Macias sells $91,782 in stock - Investing.com India

Oct 19, 2024
pulisher
Oct 19, 2024

Immunovant's chief legal officer sells $82,339 in stock By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 19, 2024

Immunovant's chief legal officer sells $82,339 in stock - Investing.com India

Oct 19, 2024
pulisher
Oct 19, 2024

Exchange Traded Concepts LLC Buys 9,438 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Oct 19, 2024
pulisher
Oct 19, 2024

Immunovant CFO Eva Renee Barnett sells $94,172 in stock - Investing.com

Oct 19, 2024
pulisher
Oct 19, 2024

Immunovant CEO Peter Salzmann sells $261,845 in shares By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 18, 2024

Immunovant CEO Peter Salzmann sells $261,845 in shares - Investing.com

Oct 18, 2024
pulisher
Oct 18, 2024

Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $91,782.52 in Stock - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Oct 16, 2024
pulisher
Oct 16, 2024

IMVT (Immunovant Inc) has impressive results - US Post News

Oct 16, 2024
pulisher
Oct 15, 2024

Raymond James gives an Outperform recommendation for Immunovant Inc (IMVT) - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Analyzing Ratios: Immunovant Inc (IMVT)’s Financial Story Unveiled - The Dwinnex

Oct 15, 2024
pulisher
Oct 14, 2024

Immunovant: Switching Lead Candidates Increases Risk (NASDAQ:IMVT) - Seeking Alpha

Oct 14, 2024

Finanzdaten der Immunovant Inc-Aktie (IMVT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Immunovant Inc-Aktie (IMVT) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Geffner Michael
Chief Medical Officer
Oct 23 '24
Sale
29.53
3,189
94,171
134,971
Stout Jay S
Chief Technology Officer
Oct 23 '24
Sale
29.53
2,740
80,912
142,186
Salzmann Peter
Chief Executive Officer
Oct 16 '24
Sale
28.79
9,095
261,845
994,789
Macias William L.
Chief Medical Officer
Oct 16 '24
Sale
28.79
3,188
91,783
365,144
Levine Mark S.
Chief Legal Officer
Oct 16 '24
Sale
28.79
2,860
82,339
327,239
Barnett Eva Renee
Chief Financial Officer
Oct 16 '24
Sale
28.79
3,271
94,172
335,343
Barnett Eva Renee
Chief Financial Officer
Oct 09 '24
Sale
29.56
5,162
152,589
338,614
Salzmann Peter
Chief Executive Officer
Oct 09 '24
Sale
29.56
4,460
131,838
1,003,884
Levine Mark S.
Chief Legal Officer
Aug 21 '24
Sale
31.86
3,295
104,976
330,099
Macias William L.
Chief Medical Officer
Aug 21 '24
Sale
31.86
3,027
96,437
368,332
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):